Roxane's Cafcit Approval Based On Post-Hoc Analysis Of Phase III Trial
Executive Summary
FDA approved Roxane's Cafcit (caffeine citrate) on Sept. 21 based on a literature review and a post-hoc analysis of secondary endpoints from a Phase III trial.